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Humanized immune system mouse models: 
progress, challenges and opportunities
On 18 December 2018, the National Institute of Allergy and Infectious Diseases convened a workshop entitled 
‘Recent Advances and Opportunities in the Development and Use of Humanized Immune System Mouse Models’.
Todd M. Allen, Michael A. Brehm, Sandra Bridges, Stacy Ferguson, Priti Kumar, Oleg Mirochnitchenko, 
Karolina Palucka, Roberta Pelanda, Brigitte Sanders-Beer, Leonard D. Shultz, Lishan Su and 
Mercy PrabhuDas
Over 30 key leaders in the field participated in a 1-day workshop entitled ‘Recent Advances and 
Opportunities in the Development and 
Use of Humanized Immune System 
Mouse Models’ to discuss the benefits 
and limitations of using human fetal 
tissue versus non-fetal tissue sources to 
generate mice with a humanized immune 
system. This Comment summarizes 
the workshop discussions, including 
highlights of some of the key advances 
made through the use of humanized mice 
in improving the understanding of immune 
system function and developing novel 
therapeutics for the treatment of infectious, 
immunological and allergic diseases, as well 
as current challenges in the production, 
characterization and utilization of these 
animal models.
Humanized mouse models
Immunocompetent mice are widely used 
in biomedical research, and use of such 
mice has supported many advances across 
multiple scientific disciplines. However, 
critical differences in the genetics and 
immune systems of mice and those of 
humans have precluded studies in mice 
of uniquely human immune responses. 
One way to address these species-specific 
differences is to conduct in vivo preclinical 
studies using immunodeficient mice 
engrafted with human cells or tissues 
— i.e., ‘humanized’ mice or ‘human 
immune system’ (HIS) mice (Fig. 1). These 
humanized mice engrafted with human 
cells and tissues serve as a preclinical bridge 
for several research areas. Engraftment 
of immunodeficient mice with human 
peripheral blood mononuclear cells 
(PBMCs), hematopoietic stem cells 
(HSCs) or human fetal tissues (thymus 
and liver) began in 1988 following the 
discovery of the Prkdcscid (severe combined 
immunodeficiency (SCID)) mutation on 
the CB17 mouse strain background1, with 
a focus on the development of a model for 
studies of human immunodeficiency virus 
(HIV). Humanized mice also have been used 
for testing the safety of drugs that target 
immunoreceptors exhibiting species-specific 
functionality. An example of this is therapy 
with antibody to the co-stimulatory receptor 
CD28, for which preclinical studies of non-
human primates did not predict the serious 
adverse events observed in the first human 
clinical trial2.
Injection of human PBMCs is the most 
direct method for developing HIS mice, 
although the expansion of human T cells is 
followed by acute xenogeneic graft-versus-
host disease. While the rapid development 
of this disease enables preclinical testing 
of human immunosuppressive agents, the 
relatively short survival of engrafted animals 
prevents long-term in vivo functional 
studies of T cells. Humanization can also 
be accomplished through the use of human 
HSCs derived from umbilical cord blood, 
bone marrow, fetal liver or adult mobilized 
HSCs. Although most HSC-engraftment 
models require preconditioning with 
sublethal X-irradiation or treatment with 
radiomimetic drugs such as busulfan, 
several newer models can support HSC 
engraftment without preconditioning. 
Improved immunodeficient mouse strains 
that lack mouse natural killer cell activity 
have been developed, such as the NOD-
PrkdcscidIl2rgtmiwjl/Sz (NSG) strain and 
related models (NOG, NRG, BRGS, etc.) 
and MISTRG mice, that all support greater 
engraftment of human lymphoid, myeloid 
and hematopoietic cells than did the earlier 
models. MISTRG mouse models represent 
an improvement in the development of the 
innate immune system relative to that of 
previous strains3,4.
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Fig. 1 | Humanized mouse models. Additional information on the humanized mouse models described 
in the text. Hu, humanized; PBL, peripheral blood lymphocyte; SRC, SCID-repopulating cell; NeoThy, 
neonatal thymus. Adapted from ref. 21.
Despite such successes, the development 
of a robust functional human immune system 
following HSC engraftment in HIS mice has 
remained constrained by numerous factors, 
including the species specificity of major 
histocompatibility complex (MHC) antigens, 
hematopoietic growth factors and cytokines, 
suboptimal development of lymphoid 
architecture and impaired class switching and 
affinity maturation of immunoglobulins.
Notably, T cell education in the thymus 
is restricted largely by mouse MHC (H-2 
complex). The development of human 
MHC (HLA)–restricted T cells can be 
accomplished through the implantation  
of fetal human thymus and liver tissue  
along with autologous fetal liver HSCs, 
which results in ‘BLT’ (bone marrow,  
liver, thymus) mice, or through the use of 
NSG mice that have transgenic expression  
of HLA molecules and are engrafted with 
partially matching cord blood HSCs3.  
Many humanized mouse models also 
express human cytokines, including SCF, 
CSF-1, GM-CSF, IL-3, IL-6, IL-7 and IL-15, 
that support enhanced differentiation 
of human myeloid and lymphoid cell 
populations3. Transgenic expression of 
human IL-34 supports the development of 
human microglia and of the brain HIV-1 
reservoir. Such advances are overcoming 
many deficiencies of the current models 
and facilitate the ability to address specific 
immunological questions (Table 1).
applications to human diseases
A few of the key areas in which humanized 
mice have contributed substantially to 
the scientific understanding of human 
disease are described below. Early studies 
of humanized mice helped to identify 
inflammatory pathways involved in the 
development of breast cancer5. However, 
improvements to relevant humanized 
mice have made it possible to study 
the more-complex interactions among 
myeloid cells, antigen-presenting cells and 
T cells, including regulatory T cells, in the 
reconstituted tumor microenvironment. 
Notably, such models have enabled the 
combination of patient-derived xenografts 
with engraftment of allogenic HSCs 
for study of the therapeutic potential 
of checkpoint inhibitors, alone or in 
combination with histone-deacetylase 
inhibitors, to reduce tumor regression.  
In addition, autologous models containing 
patient-derived xenografts and autologous 
immune cells can be used to test the efficacy 
of various immunotherapies directed 
against a patient’s own tumor and to predict 
effective treatments6.
Humanized mice offer the ability to 
investigate mechanisms of therapeutic 
effector function in vivo6 and are used 
to define mechanisms associated with 
immunotherapy toxicity that include the 
development of autoimmune antibodies. 
For example, treatment of leukemia-bearing 
humanized mice with chimeric antigen 
receptor T cells has demonstrated a key 
role for monocytes in producing IL-1 and 
IL-6 during cytokine-release syndrome7. 
Blocking the IL-6 receptor or the IL-1 
receptor controls the signs and symptoms of 
cytokine-release syndrome or neurotoxicity, 
respectively7. Thus, humanized mice 
have contributed substantially to the 
improvement of anti-cancer therapies.
Transplantation of non-self (‘allogeneic’ 
or ‘xenogeneic’) cells and tissues stimulates 
a robust host immune response that 
mediates allograft rejection. Traditional 
immunocompetent mouse models are 
effective tools with which to analyze 
immune responses directed against 
engrafted allogeneic tissues, including 
PBMCs, human T cell subsets and human 
CD34+ HSCs. Humanized mice also have 
enabled the direct study of human tissue 
rejection mediated by human immune 
cells and the testing of novel therapeutic 
strategies to prevent rejection8. HIS 
mice have been used to investigate the 
immunological rejection of human skin, 
pancreatic islets, cardiac tissues, pluripotent 
stem cell–derived populations, and 
xenografts. They also have facilitated the 
evaluation of human-specific therapeutics 
that suppress immune-system-mediated 
rejection of allografts, including CTLA4–Ig 
and monoclonal antibodies targeting CD3, 
CD28, CD154, 4-1BB, ICOS ligand and 
OX40 ligand. Moreover, such models have 
enabled the testing of human regulatory 
T cell and mesenchymal stem cell therapies 
to prevent human allograft rejection, which 
has provided insights into T cell effector 
mechanisms essential for rejection. Overall, 
HIS mouse models have become an essential 
tool for human transplantation biology 
for the testing of innovative approaches to 
prolong allograft survival.
As autoimmunity is a complex process 
that involves multiple cell types and genetic 
loci, the development of an animal model 
capable of recapitulating human autoimmune 
disease requires the establishment of a 
sophisticated human immune system in 
the mouse host. Early studies using SCID 
mice given injection of PBMCs from 
autoimmune patients demonstrated the 
occasional development of autoantibodies 
and engraftment of functional autoreactive 
T cells. Although poor B cell maturation in 
most humanized mouse models has limited 
the study of peripheral B cell tolerance, 
improved HIS mouse models given 
transplantation of human HSCs have enabled 
investigations into mechanisms of central 
lymphoid tolerance, including receptor 
editing and clonal deletion9. Humanized 
mice also support the establishment of key 
features of pristane-induced systemic lupus 
erythematosus, such as increased production 
of anti-nuclear autoantibodies and pro-
inflammatory cytokines, as well as multi-
organ and fatal autoimmunity caused by 
defective transcription factor FOXP310.  
The use of more-advanced immunocompetent 
BLT humanized mice, in which human 
T cells become educated on human HLAs, 
has facilitated the study of autoimmunity. 
For example, BLT humanized mice given 
adoptive transfer of human CD4+ T cells 
reactive to an insulin B-chain peptide 
develop insulitis and diabetes11. Therefore, 
various HIS mouse models exhibit key 
aspects of human autoimmunity that  
will be necessary for the development of 
novel therapeutics.
Humanized mouse models are perhaps 
most useful for the study of HIV, as they 
mimic human HIV infections with high 
levels of viremia and depletion of CD4+ 
T cells and also support the establishment 
of a persistent latent virus reservoir. BLT 
humanized mouse models enable the study 
of the physiologically relevant mucosal 
(intravaginal and intrarectal) and oral 
routes of HIV transmission as well as of 
anti-retroviral therapy (ART) to prevent 
transmission12. Some BLT models expressing 
distinct HLA haplotypes develop human 
HIV-specific T cell responses capable of 
selecting for viral escape mutations13.  
A humanized triple-knockout BLT mouse 
model lacking the RAG-2 recombinase 
component, the γ-chain of the IL-2 
receptor and the signal-regulatory protein 
CD47 (Rag2–/–Il2rg–/–Cd47–/– BLT mice) 
has supported the study of traditional 
small-molecule ART and non-traditional 
therapeutic approaches, such as treatment 
with interferon-α14. Humanized NSG 
mouse models have also been instrumental 
in explorations of the efficacy of gene-
modified HSCs toward a functional cure 
for HIV, including zinc-finger-mediated 
disruption of the HIV co-receptor CCR515 
and the production of HIV-specific T cells 
expressing chimeric antigen receptors15. 
Subsequently, HIS (NRG-hu Liv/Thy) mice 
served as an effective small-animal model 
with which to study combined approaches 
using vaccination and latency-reversing 
agents15, as well as broadly neutralizing 
antibodies15, to limit the HIV reservoir.
The lack of small-animal models with 
which to investigate liver disease induced 
by hepatitis B virus (HBV) or hepatitis C 
virus (HCV) has impeded delineation of the 
Table 1 | Summary of humanized mouse models
model mouse strain Human tissue application Investigator
Humanized mouse models without fetal tissue
NeoThy humanized 
mouse
NSG
NBSGW
Cryopreserved neonatal 
thymus
Umbilical cord blood
Immunogenicity studies M. Brown
NRG-Akita NOD-
Rag1nullIl2rgnullIns2Akita
Juvenile human islets; 
umbilical cord blood
Islet allotransplantation M. Brehm
NSG-Hu-PBL NSG PBMCs HIV/AIDS (long-acting drugs); gene therapy; visualizing  
HIV-1 infection
P. Kumar
NSG-HSC NSG Umbilical cord blood Arboviruses (flavivirus, alphavirus and bunyaviruses) R. Rico-Hesse
 NSG Umbilical cord blood Analysis of immunological perturbations (autoimmunity) K.C. Herold
Testing of long-acting anti-HIV therapies L. Poluektova
NOG-hIL34 Umbilical cord blood Infection of human microglia with HIV L. Poluektova
NSG or NRG HIS mice NSG, NRG Umbilical cord blood Study of B cell development and pediatric bacterial vaccines T. Manser
Mouse viral outgrowth 
assay
NSG PBMCs from HIV-
infected patients
Detection of replication-competent HIV R. Akkina
NOD SCID NOD SCID B2m–/– Adult CD34+ HSCs Adoptive T cell transfer K. Palucka
BRGS-hu BRGS Umbilical cord blood Development of colorectal cancer PDX hu mice; EBV  
type 2 infection; B cell lymphomagenesis
R. Pelanda
MISTRG Immunodeficient Rag2–/–
Il2rg–/– mice with human 
M-CSF, IL-3, GM-CSF, 
TPO and SIRPα
Umbilical cord blood Efficient development of myeloid cells and NK cells A. Rongvaux
Humanized mouse models with fetal tissue
BLT NSG Fetal liver and thymus HIV/AIDS T. Allen
Zika virus R. Akkina
Comparison of biologics; cytokine-release syndrome;  
checkpoint inhibitor adverse events
K. Howard
Vaccine and NK cell studies S. Paust
TKO-BLT TKO Fetal liver and thymus HIV–AIDS K. Hasenkrug
NSG-SGM3-BLT NSG-SGM3 Fetal liver and thymus Development of human mast cells for anaphylaxis studies;  
human macrophage–mediated fibrosis in would healing
M. Brehm
NSG-HSC NSG HSCs from fetal liver Mouse skin transplant model; type 1 diabetes; aberrant  
immune responses; microbiota control
K.C. Herold
NSG or NRG HIS mice NSG, NRG HSCs from fetal liver Study of B cell development and pediatric bacterial vaccines T. Manser
SCID-hu Thy/Liv C.B-17 scid Fetal liver and thymus Isolation of candidate human stem cell populations and CNS  
stem cells; growth of cancer stem cells in mice; HIV–AIDS
Weissman I
AFC-hu HSC/Hep AFC8/BRG Hepatocytes and HSCs 
from fetal liver
Human liver fibrosis after HCV infection L. Su
A2/NSG-hu HSC/Hep A2/NSG Hepatocytes and HSCs 
from fetal liver
Human liver fibrosis after HBV infection L. Su
Human microglia mouse NOG-hIL34 Fetal brain and liver 
tissue
Study of neurotropic infections, such as infection with  
HIV, CMV, Zika virus, JCPyV
L. Poluektova
Fetal human thymus 
mouse model
NSG Fetal human thymus 
plus CD34+ cells
Study of T cell homeostasis, Treg cell development, human  
T cell repertoire development, transplantation tolerance,  
in vivo analysis of human immune responsiveness
M. Sykes
UCLA service core BLT, SCID-hu, hu-PBL 
SCID, NOG-hu, BLT-
NOD.SCID, HIS-DKO, 
NRG-BLT
Fetal liver and thymus IND-enabling studies in HIV–AIDS, oncology,  
hematopoietic disorders, gene therapy, immunotherapy,  
and infectious disease
S. Kitchen
NBSGW, NOD.Cg-KitW-41JTyr + PrkdcscidIl2rgtm1Wjl/ThomJ; TKO, B6.129S-Rag2tm1FwaCd47tm1FplIl2rgtm1Wjl/J; NRG, NOD.Cg-Rag1tm1MomIl2rgtm1Wjl/SzJ; BRGS, BALB/c Rag2tm1FwaIl2rgtm1CgnSirpaNOD; MISTRG, C;129S4-
Rag2tm1.1FlvCsf1tm1(CSF1)FlvCsf2/Il3tm1.1(CSF2,IL3)FlvThpotm1.1(TPO)FlvIl2rgtm1.1FlvTg(SIRPA)1Flv/J; B2m, gene encoding β2-microglobulin; EBV, Epstein–Barr virus; CMV, cytomegalovirus; CNS, central nervous system; JCPyV, JC 
polyomavirus; KO, knockout; PDX, patient-derived xenograft; NK, natural killer; Treg cell, regulatory T cell; IND, investigational new drug.
virological and immunological mechanisms 
of viral persistence and efficient testing 
of new therapeutics. Humanized mouse 
models engrafted with human immune cells, 
human hepatocytes and hepatic stellate cells 
have been developed that support infection 
with HBV or HCV and the subsequent 
immunopathogenesis. When infected with 
HBV, such engrafted mice mount virus-
specific immune responses and develop 
histopathological features reminiscent 
of human liver disease associated with 
pathogenic M2-like macrophages16. The 
low level of human hepatocyte development 
from fetal hepatocytes and low HBV 
replication have been improved through 
engraftment of adult hepatocytes and 
allogeneic human fetal HSCs17.
Humanized mice are useful for the 
investigation of other viruses beyond 
HIV, HBV and HCV18. Humanized mice 
infected with the herpesvirus Epstein–Barr 
virus (EBV) enable modeling of B cell 
lymphoproliferative disease and EBV-driven 
lymphoma formation. Clinical features 
of hemophagocytic lymphohistiocytosis 
and erosive arthritis associated with 
EBV infection also can be recapitulated 
in humanized mice, which has led to 
the investigation of therapies for these 
conditions. Human cytomegalovirus, 
another herpesvirus, can establish latent 
infection in humanized mice in a way 
similar to its establishment in humans, 
including reactivation after treatment with 
G-CSF, which has enabled the study of this
virus and its control with antiviral agents.
Additionally, Dengue virus, a mosquito-
borne flavivirus, can successfully infect
humanized mice and establish clinical signs
such as fever and erythema. Dengue virus–
infected mosquitoes can model transmission
via bite in humanized mice, which results
in higher viremia and a severe form of the
disease19. Humanized mice also are capable
of supporting infection with Zika virus and
developing Zika virus–specific antibody
responses, which has provided a model
with which to test antiviral therapeutics20.
Therefore, humanized mouse are capable of
supporting infection with and immunity to
various human viruses, which facilitates the
testing of therapeutic interventions.
While parasitic and bacterial pathogens are 
generally less host specific than are viruses, 
humanized mice have proven useful for 
studies of certain microbes, particularly when 
human hematopoietic and immune cells exert 
a strong influence on their pathogenesis. 
Similarly, humanized mice support infection 
with Neisseria meningitidis and develop 
vascular damage18, including the release of 
pro-inflammatory cytokines that leads to 
neutrophil infiltration and inflammation and 
results in skin-graft pathology. Several groups 
have also used humanized mouse models to 
study infection with Salmonella typhi and 
dissemination of this bacteria to multiple 
organs18. Humanized mice also support 
infection with and immunity to Leishmania 
major, Borrelia hermsii and some strains of 
Streptococcus18. Thus, humanized mice also 
aid in understanding of the pathogenesis  
and treatment of human bacterial and 
parasitic infections.
Challenges, alternatives and strategies
Humanized mouse models, generated with 
either fetal human tissues or non-fetal 
human tissues, have dramatically improved 
the ability to study human diseases. 
However, discussions at the meeting made 
it clear that no single model is sufficient to 
support the broad array of research areas 
described above. Many of these models also 
have numerous limitations, including the 
potential for xeno-reactive graft-versus-
host disease and its ensuing complications; 
limited lifespan; incomplete human 
immune function, including a lack of B cell 
immunoglobulin G responses; low levels of 
human-cell reconstitution of gut-associated 
lymphoid tissues; and underdeveloped 
lymphoid organs and poorly developed 
lymphoid architecture. These issues 
need to be carefully considered in the 
interpretation of experimental results. Fetal 
tissue–based BLT humanized mice pose 
additional practical limitations that include 
the following: access to adequate amounts 
of tissue; tissue collection and storage 
requirements; reproducibility; and broad 
availability to the research community. 
Nonetheless, the availability of a small-
animal model greatly facilitates the conduct 
of rapid, iterative studies.
Humanized mice generated from non-
fetal cells and tissues (for example, neonatal 
or adult stem cells, or umbilical cord blood) 
have been used for specific indications.  
These newer models need further develop-
ment, as they currently do not recapitulate 
the immune-system functionality observed 
in fetal tissue–based BLT humanized mice. 
Careful head-to-head (direct) comparisons of 
humanized mice constructed with HSCs and 
different sources of human tissues are needed 
for better understanding of the potential of 
the various model systems to recapitulate 
critical human immune responses across an 
array of human diseases.
Conclusions and next steps
Humanized mice have become an important 
tool for many research applications, 
including human immune function, 
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Fig. 2 | areas that require development and optimization in HIS mice. Areas in the field that need 
more development and study of humanized mice that better recapitulate and/or reflect human immune 
responses; these can be used for better understanding of infectious disease, autoimmunity and cancer 
development and for the evaluation of therapies. GVHD, graft-versus-host disease. 
infectious diseases, autoimmune diseases, 
cancer, and organ or tissue transplantation. 
In addition to the need for direct 
comparisons of humanized mice generated 
with fetal tissue and those generated with 
non-fetal tissue, improving current HIS 
mouse models to better recapitulate the 
human immune system has the potential to 
lead to new biological insights and permit 
the assessment of new biological therapies 
(Fig. 2). The US National Institutes of Health 
is committed to supporting studies that 
develop humanized mouse models that do 
not rely on human fetal tissue and faithfully 
represent the human immune system (as 
indicated in the notices NOT-AI-19-040 and 
NOT-OD-19-042 and an announcement of 
concept clearance (https://www.niaid.nih.
gov/grants-contracts/january-2019-dait-
council-approved-concepts#07)). ❐
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